Fig. 3 | Nature Medicine

Fig. 3

From: Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial

Fig. 3

Tree graph describing ctDNA RAS/BRAF/EGFR status of patients screened for CHRONOS enrollment according to the time interval between the end of the last anti-EGFR course and the date of the CHRONOS ctDNA screening. Top: patients with WT sample; color-coded objective response to rechallenge with panitumumab on a time scale displaying PFS. Bottom: patients with mutated sample and mutations retrieved leading to CHRONOS screening failure. αEGFR, anti-EGFR. Abbreviations: MT, mutant; WT, wild-type.

Back to article page